The Phenotype of Bone Turnover in Patients with Fragility Hip Fracture: Experience in a Fracture Liaison Service Population.


Journal

International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455

Informations de publication

Date de publication:
15 06 2022
Historique:
received: 12 05 2022
revised: 11 06 2022
accepted: 14 06 2022
entrez: 24 6 2022
pubmed: 25 6 2022
medline: 28 6 2022
Statut: epublish

Résumé

Background: Hip fragility fractures are becoming one of the main health care problems in countries with an aging population. This study aimed to evaluate the clinical characteristics and the usefulness of bone turnover markers in patients with a hip fracture. Methods: In a cohort of 363 patients (84.1 ± 9.2 years) with hip fractures we measured 25-hydroxyvitamin D (25OHD), bone alkaline phosphatase, type I collagen β carboxy telopeptide (βCTX), and parathyroid hormone (PTH). We recorded patients’ Charlson Comorbidity Index (CCI) and previous history of fragility fractures. Results: Vitamin D and PTH levels were inversely correlated (r = −024; p < 0.001). The prevalence of 25OHD deficiency was 57.8%, the PTH levels greater than 65 pg/mL was in 47.0 %, and in those who had βCTX values the upper limit was 61.8%. Moreover, 62% of patients with a fragility hip fracture had a history of a previous fracture. The 25OHD serum levels were inversely associated with CCI and a previous fragility fracture. On the contrary, PTH and βCTX serum levels showed a positive significant correlation with CCI and previous fragility fractures. Conclusion: This study confirmed the usefulness of a bone turnover markers assessment, along with the comorbidities and history of previous fragility fractures in order to better identify the risk of hip fracture.

Identifiants

pubmed: 35742610
pii: ijerph19127362
doi: 10.3390/ijerph19127362
pmc: PMC9223564
pii:
doi:

Substances chimiques

Parathyroid Hormone 0
Vitamin D 1406-16-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Osteoporos Int. 2013 Apr;24(4):1151-9
pubmed: 23011681
Bone. 2010 Aug;47(2):400-7
pubmed: 20451678
BMC Fam Pract. 2018 Aug 23;19(1):141
pubmed: 30139341
J Am Med Dir Assoc. 2015 Aug 1;16(8):715.e7-715.e12
pubmed: 26142060
J Endocrinol Invest. 2015 Oct;38(10):1129-35
pubmed: 26048596
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Lancet. 2019 Jan 26;393(10169):364-376
pubmed: 30696576
Rev Clin Esp. 2007 Oct;207(9):464-8
pubmed: 17915170
Osteoporos Int. 2006;17(11):1608-14
pubmed: 16874442
Osteoporos Int. 2013 Feb;24(2):641-9
pubmed: 22581296
Aging Clin Exp Res. 2019 Oct;31(10):1501-1507
pubmed: 30701437
Bone. 1996 Mar;18(3 Suppl):133S-137S
pubmed: 8777078
Osteoporos Int. 2003 Sep;14(9):780-4
pubmed: 12904835
Rev Endocr Metab Disord. 2020 Mar;21(1):89-116
pubmed: 32180081
Injury. 2018 Aug;49(8):1398-1402
pubmed: 29921533
Osteoporos Int. 2013 Feb;24(2):393-406
pubmed: 22829395
Aging Clin Exp Res. 2020 Dec;32(12):2587-2593
pubmed: 32056151
N Engl J Med. 2017 Nov 23;377(21):2053-2062
pubmed: 29166235
Osteoporos Int. 2002 Aug;13(8):624-9
pubmed: 12181620
Med Care. 2015 Sep;53(9):e65-72
pubmed: 23703645
J Clin Rheumatol. 2022 Jan 1;28(1):e49-e55
pubmed: 32956158
Injury. 2018 Apr;49(4):829-840
pubmed: 29559183
Bone. 2004 Aug;35(2):375-82
pubmed: 15268886
Lancet. 2002 May 18;359(9319):1761-7
pubmed: 12049882
Aging Clin Exp Res. 2017 Oct;29(5):1031-1037
pubmed: 27943127
Hormones (Athens). 2021 Sep;20(3):545-555
pubmed: 33619705
Maturitas. 2014 Nov;79(3):299-305
pubmed: 25124531
Calcif Tissue Int. 2014 Oct;95(4):340-8
pubmed: 25139040
Calcif Tissue Int. 2015 Dec;97(6):560-7
pubmed: 26254556
J Nutr Health Aging. 2013 Feb;17(2):180-4
pubmed: 23364499
Clin Orthop Relat Res. 2007 Aug;461:226-30
pubmed: 17415014
Endocr Rev. 2001 Aug;22(4):477-501
pubmed: 11493580
Bone. 2008 Mar;42(3):597-602
pubmed: 18180211
Br J Clin Pharmacol. 2018 Oct;84(10):2194-2207
pubmed: 29851137

Auteurs

Carla Caffarelli (C)

Department of Medicine, Surgery and Neuroscience, Section of Internal Medicine, University of Siena, 53100 Siena, Italy.

Nicola Mondanelli (N)

Department of Medicine, Surgery and Neurosciences, Section of Orthopedics and Traumatology, University of Siena, 53100 Siena, Italy.

Eduardo Crainz (E)

Department of Orthopaedics and Traumatology, Section of Orthopedics and Traumatology, University Hospital of Siena, 53100 Siena, Italy.

Stefano Giannotti (S)

Department of Medicine, Surgery and Neurosciences, Section of Orthopedics and Traumatology, University of Siena, 53100 Siena, Italy.

Bruno Frediani (B)

Department of Medicine, Surgery and Neurosciences, Rheumatology Unit, University of Siena, 53100 Siena, Italy.

Stefano Gonnelli (S)

Department of Medicine, Surgery and Neuroscience, Section of Internal Medicine, University of Siena, 53100 Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH